NASDAQ:CBLI - Cleveland BioLabs Stock Price, Forecast & News

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its quarterly earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) EPS for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Cleveland BioLabs had a negative return on equity of 93.20% and a negative net margin of 241.79%. View Cleveland BioLabs' Earnings History.

Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cleveland BioLabs.

Media stories about CBLI stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cleveland BioLabs earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Cleveland BioLabs.

Cleveland BioLabs saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 27,200 shares, a decrease of 43.0% from the January 15th total of 47,700 shares. Based on an average daily volume of 280,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.6% of the shares of the stock are short sold. View Cleveland BioLabs' Current Options Chain.

Some companies that are related to Cleveland BioLabs include Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), US Stem Cell (USRM), Vitality Biopharma (VBIO), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Actinium Pharmaceuticals (ATNM), Novavax (NVAX) and Tonix Pharmaceuticals (TNXP).

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBLI stock can currently be purchased for approximately $1.94.

Cleveland BioLabs has a market capitalization of $21.92 million and generates $1.14 million in revenue each year. View Additional Information About Cleveland BioLabs.

The official website for Cleveland BioLabs is http://www.cbiolabs.com/.

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]